Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 27/06/2024 BST 		5-day change 1st Jan Change
1.37 USD -2.84% Intraday chart for Inhibikase Therapeutics, Inc. -4.20% +7.87%
06-17 Inhibikase Therapeutics Completes Enrollment of the Phase 2 ?201? Trial Evaluating Risvodetinib in Untreated Parkinson?s Disease CI
06-05 Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline CI

Business Summary

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.

Number of employees: 9

Sales per Business

USD in Million2022Weight2023Weight Delta
Protein Kinase Inhibitor Therapeutics
100.0 %
0 100.0 % 0 100.0 % +111.03%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % +111.03%

Managers

Managers TitleAgeSince
Milton Werner FOU
 Founder 61 31/08/08
C. Warren Olanow CTO
 Chief Tech/Sci/R&D Officer - 03/01/21
Dan Williams AUD
 Comptroller/Controller/Auditor - -
Surendra Singh PRN
 Corporate Officer/Principal - 31/07/14
W. Roger Rush PRN
 Corporate Officer/Principal - 31/12/14
Merrill M. Kraines LAW
 General Counsel - -

Members of the board

Members of the board TitleAgeSince
Dennis Berman BRD
 Director/Board Member 73 31/08/19
Paul Grint BRD
 Director/Board Member 66 21/12/20
Milton Werner FOU
 Founder 61 31/08/08
Gisele Dion BRD
 Director/Board Member 57 31/08/22
Roy Freeman BRD
 Director/Board Member 72 21/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 7,216,145 6,318,888 ( 87.57 %) 0 87.57 %

Shareholders

NameEquities%Valuation
Milton Werner
12.32 %
889,242 12.32 % 2 M $
Armistice Capital LLC
8.281 %
597,575 8.281 % 1 M $
FiveT Capital AG
3.097 %
223,500 3.097 % 411 240 $
William Blair & Co. LLC
1.062 %
76,601 1.062 % 140 946 $
Geode Capital Management LLC
0.3976 %
28,692 0.3976 % 52 793 $
G1 Execution Services LLC
0.3134 %
22,616 0.3134 % 41 613 $
Renaissance Technologies LLC
0.2969 %
21,422 0.2969 % 39 416 $
Redmond Asset Management LLC
0.2711 %
19,560 0.2711 % 35 990 $
Vanguard Group, Inc. (Subfiler)
0.2318 %
16,724 0.2318 % 30 772 $
Timber Point Capital Management LLC
0.1524 %
11,000 0.1524 % 20 240 $

Company contact information

Inhibikase Therapeutics, Inc.

3350 Riverwood Parkway South East Suite 1900

30339, Atlanta

+678 392 3419

http://www.inhibikase.com
address Inhibikase Therapeutics, Inc.(IKT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.37 USD
Average target price
15.5 USD
Spread / Average Target
+1,031.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INHIBIKASE THERAPEUTICS, INC. Stock Inhibikase Therapeutics, Inc.
+7.87% 9.89M
MODERNA, INC. Stock Moderna, Inc.
+21.85% 46.44B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.1B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.76B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 31.24B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 25.8B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 25.9B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 13.12B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 10.68B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IKT Stock
  4. Company Inhibikase Therapeutics, Inc.